Latest News | Richmond Pharmacology

Low data variability

Our core ECG laboratory provides a centralised system for all our studies. High precision ECG acquisition in our clinic provides meaningful ECG analysis with a smaller sample size, making us the ideal choice for the integration of cardiac safety in FIH and MAD studies.

We are a leading publisher in cardiology and have publicly accessible credentials. We are proud of our integrity, our professional growth and experience in this field.

Learn more about our ECG Lab

Exceptional ECG generation

We undertake and analyse several cardiological assessments using state-of-the-art equipment to understand and explain abnormal ECG data obtained during a clinical study of a new chemical entity.

Learn more about our Cardio Analysis Services

Experts in cardiac safety

Richmond Pharmacology’s Core ECG Laboratory team are based within St George’s Hospital Medical School, London and are made up of highly experienced cardiologists headed by Professor John Camm, a key opinion leader in TQT Trials.

Learn more about our expert cardiologists

Richmond team to take part in the MS Society Wheel & Walk at Windsor Great Park

8

July 2007

Joint AHPPI and ICR Meeting

5

July 2007

Accreditation of Phase I units in the UK

15

May 2007

Improving Safety in Phase I Trials - Planning Your Early Phase Development?

24

April 2007

Safety and Risk Management in Translational Medicine

3

March 2007

Calling all Clinical Phase I Outsourcing Professionals!

4

February 2007

Meet the experts

Richmond Pharmacology has a team of experts with extensive knowledge of clinical research trials.

Careers at Richmond

We are on the lookout for people who love what they do, strive for excellence and who want to make a difference.

Our Videos

Learn more about Richmond Pharmacology by viewing some of our videos.

Latest news

Richmond Appoints Lisa Campbell as Director of Regulatory Strategy

April 23, 2025

Richmond Pharmacology is pleased to announce the appointment of Lisa Campbell as Director of Regulatory Strategy

Von Willebrand Disease Trial – First Stage of Hemab Therapeutics’ Trial Completed and New Patients Invited to Enrol

April 2, 2025

Richmond has completed dosing the first cohort of patients in Velora Pioneer, a phase 1/2 clinical trial investigating Hemab...

Events

Swiss Biotech Day 2025

5–6 May 2025

Richmond Pharmacology is pleased to confirm our participation at Swiss Biotech Day 2025